Late of Sunday, Emergent BioSolutions Inc said, a key U.S. agency has increased an order related to the manufacturing of Johnson & Johnson’s COVID-19 vaccine, by $23 million.

“The amount will be used to purchase biologics equipment specific to J&J’s vaccine and support the potential manufacturing expansion at the company’s Baltimore Bayview facility,” said the company in a statement while adding, ramping up manufacturing of AstraZeneca Plc’s COVID-19 vaccine bulk drug substance, is also on the cards.

Categories: Creativity, Entrepreneurship, HR & Organization, Strategy

Tags: AstraZeneca Plc, Baltimore Bayview, biologics, COVID-19, COVID19, Emergent BioSolutions Inc, equipment, expansion, facility, J&J’s vaccine, Johnson & Johnson, manufacturing, plant, production, support, vaccine